ORMP ORAMED PHARMACEUTICALS INC Operational Disruptions 8-K Filing 2023 - Phase 3 Clinical Trial Results ORAMED PHARMACEUTICALS INC. announced Phase 3 results of its clinical trial for its oral insulin capsule, ORMP-0801, which did not meet its primary and secondary endpoints, leading to the discontinuation of its oral insulin clinical activities for Type 2 Diabetes.Get access to all SEC 8-K filings of the ORAMED PHARMACEUTICALS INC